Medical cannabis company Zelira Therapeutics Ltd ZLD ZLDAF has just announced the launch of its HOPE line of products for autism in Australia.
The HOPE range of products will be distributed nationally via Health House Holdings. They will be available to Australian patients through a prescription issued via the country’s Therapeutic Goods Administration (TGA) Special Access Scheme (SAS).
The SAS allows authorized doctors to prescribe therapeutic goods that are otherwise unapproved for general access in Australia’s health care system. In most of Australia, such authorization is required in order to prescribe medicinal cannabis products to their patients.
The HOPE products were first launched in in Pennsylvania in 2019, when Zelira licensed its proprietary formulas to Ilera Healthcare, with the support of HOPE Grows for Autism, a leading advocacy group for autism spectrum disorder (ASD) based in Pennsylvania. In August 2020, HOPE launched in Louisiana under license in Louisiana in partnership with llera Holistic Healthcare.
“HOPE was formulated to help support the unmet needs of the ASD community worldwide, and we are excited to bring these products to patients and physicians in Australia after our successful American launches,” Dr. Richard Hopkins, Managing Director for the company outside the U.S., told Benzinga.
“After launching in Pennsylvania last year and most recently in Louisiana, HOPE is quickly establishing itself as one of the top-selling formulated medicinal cannabis products,” added Oasagie Imasogie, Chairman of Zelira Therapeutics. “This confirms that there is a real demand for cannabinoid-based treatments for the ASD community, and we look forward to working with our stakeholders worldwide to ensure they can access the benefits that medicinal cannabis can provide.”
Courtesy photo.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Missed the first wave of cannabis investments? Don’t make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:
- 47.10% with $GTBIF
- 40.23% with $TCNNF
- 21.50% with $VFF
But here's the kicker: Michael is about to release his next potential winners, and he's chomping at the bit to share these ticker symbols with you ASAP.
Don't miss out on the green rush!